Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alto Neuroscience (ANRO) Short term Debt (2024 - 2026)

Alto Neuroscience has reported Short term Debt over the past 3 years, most recently at $2.1 million for Q1 2026.

  • Quarterly results put Short term Debt at $2.1 million for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was $2.1 million (changed N/A YoY), and the annual figure for FY2025 was $585000.0, changed.
  • Short term Debt reached $2.1 million in Q1 2026 per ANRO's latest filing, up from $585000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $3.5 million in Q3 2024 and bottomed at $585000.0 in Q4 2025.
  • Median Short term Debt over the past 3 years was $2.1 million (2026), compared with a mean of $1.9 million.